277 related articles for article (PubMed ID: 18829780)
1. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory.
Conway J; Wong KK; O'Connell C; Warren AE
Pediatrics; 2008 Oct; 122(4):e828-34. PubMed ID: 18829780
[TBL] [Abstract][Full Text] [Related]
2. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
[TBL] [Abstract][Full Text] [Related]
3. Stimulants and sudden death: what is a physician to do?
Wilens TE; Prince JB; Spencer TJ; Biederman J
Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
[TBL] [Abstract][Full Text] [Related]
4. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
[TBL] [Abstract][Full Text] [Related]
5. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
6. Impact of the American Heart Association scientific statement on screening electrocardiograms and stimulant medications.
Thomas PE; Carlo WF; Decker JA; Cannon BC; Kertesz NJ; Friedman RA; Kim JJ
Arch Pediatr Adolesc Med; 2011 Feb; 165(2):166-70. PubMed ID: 21300657
[TBL] [Abstract][Full Text] [Related]
7. Paediatricians' decision making about prescribing stimulant medications for children with attention-deficit/hyperactivity disorder.
Chow SJ; Sciberras E; Gillam LH; Green J; Efron D
Child Care Health Dev; 2014 May; 40(3):301-8. PubMed ID: 23445484
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
Perrin JM; Friedman RA; Knilans TK; ;
Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
[No Abstract] [Full Text] [Related]
10. Overcoming the barriers to effective treatment for attention-deficit/hyperactivity disorder: a neuro-educational approach.
Monastra VJ
Int J Psychophysiol; 2005 Oct; 58(1):71-80. PubMed ID: 15927296
[TBL] [Abstract][Full Text] [Related]
11. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
Wooltorton E
CMAJ; 2006 Jul; 175(1):29. PubMed ID: 16772535
[No Abstract] [Full Text] [Related]
12. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (For).
Isaacs D
J Paediatr Child Health; 2006 Sep; 42(9):544-7. PubMed ID: 16925542
[TBL] [Abstract][Full Text] [Related]
13. Changes in medications administered in schools.
McCarthy AM; Kelly MW; Johnson S; Roman J; Zimmerman MB
J Sch Nurs; 2006 Apr; 22(2):102-7. PubMed ID: 16563033
[TBL] [Abstract][Full Text] [Related]
14. Stimulant medication in pre-school children in New South Wales.
Eysbouts Y; Poulton A; Salmelainen P
J Paediatr Child Health; 2011 Dec; 47(12):870-4. PubMed ID: 21658150
[TBL] [Abstract][Full Text] [Related]
15. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.
Warren AE; Hamilton RM; Bélanger SA; Gray C; Gow RM; Sanatani S; Côté JM; Lougheed J; LeBlanc J; Martin S; Miles B; Mitchell C; Gorman DA; Weiss M; Schachar R
Can J Cardiol; 2009 Nov; 25(11):625-30. PubMed ID: 19898693
[TBL] [Abstract][Full Text] [Related]
16. Electrocardiographic screening in children with attention-deficit hyperactivity disorder.
Mahle WT; Hebson C; Strieper MJ
Am J Cardiol; 2009 Nov; 104(9):1296-9. PubMed ID: 19840580
[TBL] [Abstract][Full Text] [Related]
17. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
Faraone SV; Wilens TE
J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
Newcorn JH; Donnelly C
Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
[No Abstract] [Full Text] [Related]
19. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (Against).
Efron D
J Paediatr Child Health; 2006 Sep; 42(9):548-51. PubMed ID: 16925543
[TBL] [Abstract][Full Text] [Related]
20. A controlled study of autonomic nervous system function in adults with attention-deficit/hyperactivity disorder treated with stimulant medications: results of a pilot study.
Schubiner H; Hassunizadeh B; Kaczynski R
J Atten Disord; 2006 Nov; 10(2):205-11. PubMed ID: 17085631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
